Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | ME2 | P23368 | 1/20 | 0.40 |
| ▸ | ME1 | P48163 | 1/20 | 0.40 |
| ▸ | ME3 | Q16798 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12809334 | 0.78 | RPS6KB2 (0.56) | CYP2A6AGXTADRB2ASIC3LOXL2 | |
| SCHEMBL6750443 | 0.77 | AGXT (0.41) | AGXTLOXL2NAMPTTAS1R3TAS1R1 | |
| SCHEMBL4510014 | 0.74 | CYP2A6 (0.58) | CYP2A6AGXTADRB2ASIC3LOXL2 | |
| SCHEMBL6750366 | 0.74 | POLB (0.43) | LMNAGAARAB9A | |
| SCHEMBL187684 | 0.73 | ALOX5 (0.51) | HDAC2HDAC8HDAC6ALOX5LMNA | |
| SCHEMBL9743497 | 0.73 | CYP4F2 (0.49) | CYP2A6AGXTADRB2ASIC3LOXL2 | |
| SCHEMBL6748902 | 0.73 | POLB (0.33) | CYP1A2LMNAGAA | |
| SCHEMBL126901 | 0.72 | LOXL2 (0.44) | LOXL2HDAC1HDAC8HDAC6CYP1A2 | |
| SCHEMBL6750445 | 0.72 | BTN3A1 (0.33) | CYP1A2LMNARAB9A | |
| SCHEMBL7991033 | 0.70 | FFAR1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044045-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN, INC. | 2004-03-04 | — | — | US | disclosed |
| US-6602900-B2 | F-type prostaglandins as ocular hypotensives | ALLERGAN, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020198249-A1 | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN SALES, INC. | 2002-12-26 | — | — | US | disclosed |
| US-6310087-B2 | TREATING GASTRIC OR DUODENAL ULCER, OSTEOPOROSIS, CONSTIPATION, RENAL DISORDERS, SEXUAL DYSFUNCTION, BALDNESS, DIABETES, CANCER AND DISORDER OF IMMUNE REGULATION | ALLERGAN SALES, INC. | 2001-10-30 | — | — | US | disclosed |
| US-20010016597-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN SALES, INC. | 2001-08-23 | — | — | US | disclosed |
| EP-0825980-B1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLAKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION | ALLERGAN SALES INC (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6204287-B1 | TREATING VISION DEFECTS | ALLERGAN SALES, INC. | 2001-03-20 | — | — | US | disclosed |
| US-6037364-A | ADMINISTERING OCULAR HYPOTENSIVE AGENT; TREATING CARDIOVASCULAR DISORDERS; ANTICOAGULANTS | ALLERGAN SALES, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| US-5972991-A | ADMINISTERING TO THE MAMMAL SUFFERING FROM OCULAR HYPERTENSION A F-TYPE PROSTAGLANDIN DERIVATIVE | ALLERGAN (US) | 1999-10-26 | — | — | US | disclosed |
| US-5834498-A | OCULAR HYPOTENSIVE AGENTS | ALLERGAN (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0825980-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLAKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION | Allergan (US) | 1998-03-04 | — | — | EP | disclosed |
| WO-1996036599-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION | ALLERGAN (US) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044045-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | PTGER1, PTGFR, PTGER2 | CYP2A6 103/4885AGXT 3543/4885ADRB2 27/4885 |
| US-20010016597-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | PTGER1, PTGER2, PTGFR | CYP2A6 217/4885AGXT 3091/4885ADRB2 30/4885 |
| US-20020198249-A1 | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | PTGER1, PTGFR, PTGER2 | CYP2A6 105/4885AGXT 3533/4885ADRB2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.